- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03752346
Multimodal Exercise Program on Parkinson's Disease Patients With Depression
Effectiveness of Multimodal Exercise Program on Depression and Health-Related Quality of Life in Patients With Parkinson's Disease
Study Overview
Detailed Description
Objective: Evaluate the effectiveness of a 8-week multimodal exercise program on depression and HRQOL in PD Patients.
Methods: Single-blinded, randomized controlled trial, from March 2016 to January 2017. Ninety-eight patients recruited to 2 groups: exercise group (n = 49) and control group (n = 49). The primary outcomes were depression and HRQOL; the secondary outcomes were activity of daily living, motor ability, fatigue, sleep quality and anxiety. Data collection at baseline, week 4 and 8 after intervention. Intervention were Multimodal Exercise Program, at least three times (30 - 50 minutes per section) a week or 10-15 minutes per section every day to accumulate 150 minutes a week for 8 weeks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- be diagnosed PD in Hoehn and Yahr stage I-II22
- under stable medication treatment at least 3 months
- no disease limiting the patient's ability to perform the exercises
Exclusion Criteria:
- severe cardiovascular disorders
- neuromusculoskeletal disorder
- cognitive impairment
- recent participation in any physiotherapy or rehabilitation program
- have exercise regularly
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: control group
Control group maintained their regular lifestyle and received the routine care
|
|
|
Experimental: exercise group
Participants in the exercise group (EG) were instructed to engage performed exercise at least 3 times per week (30-50 minutes) or 10-15 minutes per section every day to accumulate 150 minutes per week for 8 weeks using disc (DVD) at home.
Main exercise was moderate intensity aerobic exercise, an intensity of 55-70% of the heart rate reserve (HR max).
|
A step aerobics exercise lasted a total 30 minutes, including:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
GDS-15
Time Frame: 3 minutes
|
consisting of 15 questions, was the primary outcome evaluator (Sheikh and Yesavage, 1986).
Scores of 0-4 are considered to be normal; 5-8 indicates mild depression; 9-11 indicates moderate depression; and 12-15 indicates severe depression.
|
3 minutes
|
|
PDQ-8
Time Frame: 3 minutes
|
A sub-set of items is then selected from the PDQ-39 to create a shorter form version, the PDQ-8 (Jenkinson, Fitzpatrick & Peto, 1997).
The sum of the scores can provide a single figure used to assess the overall health-related quality of life profile of the individual questioned. .
Scores for each dimension range from 0 to 100, PDQ-8SI scores can be standardized on a scale from 0 to 100, with lower scores indicating better HRQoL.
|
3 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
UPDRS part II (ADL)
Time Frame: 5 minutes
|
The unified Parkinson's disease rating scale (UPDRS) is used to follow the longitudinal course of Parkinson's disease (Fahn & Elton, 1987).
The UPD rating scale is the most commonly used scale in the clinical study of Parkinson's disease.
A total of 199 points are possible (199 represents the worst disability and 0 no disability).
Part II: self-evaluation of the activities of daily life (ADLs).
The scales part 2: motor experiences of daily living (13 items), each subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe.
|
5 minutes
|
|
UPDRS part III (motor ability)
Time Frame: 10 minutes
|
The unified Parkinson's disease rating scale (UPDRS) is used to follow the longitudinal course of Parkinson's disease (Fahn & Elton, 1987).
The UPD rating scale is the most commonly used scale in the clinical study of Parkinson's disease.
Its 42 items are evaluated by interview and clinical observation.
The motor section in particular to follow the progression of a person's Parkinson's disease.
A total of 199 points are possible (199 represents the worst disability and 0 no disability).
The scales part 3: motor examination (18 items), each subscale now has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe.
|
10 minutes
|
|
Fatigue (FSS)
Time Frame: 5 minutes
|
The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue (Krupp, LaRocca, Muir-Nash, & Steinberg, 1989).
The subject is asked to read each statement and circle a number from 1 to 7, the items are scored on a 7 point scale with 1=strongly disagree and 7=strongly agree.
The minimum score=9 and maximum score possible=63.
Higher the score=greater fatigue severity.
|
5 minutes
|
|
Sleep quality (PSQI)
Time Frame: 5 minutes
|
The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep in adults (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989).
It differentiates "poor" from "good" sleep quality by measuring seven areas (components): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction over the last month.
A total score of "5" or greater is indicative of poor sleep quality.
|
5 minutes
|
|
Anxiety (HAS)
Time Frame: 3 minutes
|
The Hospital Anxiety Scale (HAS), a self-assessment scale, was developed to detect states of, anxiety and emotional distress, used to screen for the presence of anxiety, in a general medical population of patients (Zigmond & Snaith, 1983).
Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety.
For both scales, scores of less than 7 indicate normal, 8-10 indicate mild anxiety, 11-14 indicate moderate anxiety and 15-21 severe anxiety.
|
3 minutes
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 151223
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
EicOsis Human Health Inc.University of California, Davis; Michael J. Fox Foundation for Parkinson's...RecruitingParkinson's Disease (PD)United States
-
University of Kansas Medical CenterNot yet recruitingParkinson's Disease (PD)United States
-
AbbVieRecruiting
-
University Hospital Schleswig-HolsteinUniversity of Kiel; University of Cologne; University Hospital, Bonn; Philipps...Not yet recruitingParkinson's Disease (PD)
-
InvicroMerck Sharp & Dohme LLCRecruitingParkinson's Disease | Parkinson's Disease (PD) | Parkinson's Disease (Disorder)United States
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Guangzhou Henovcom Bioscience Co. Ltd.Frontage Clinical Services, Inc.Active, not recruitingParkinson's Disease (PD)United States
-
Universitätsklinikum Hamburg-EppendorfUniversity of TwenteRecruitingParkinson's Disease | Deep Brain StimulationGermany
-
Mission TherapeuticsMichael J. Fox Foundation for Parkinson's Research; Parkinson's UKRecruitingParkinson's Disease (PD) | Early Stage Parkinson's Disease | Mild to Moderate Parkinson's DiseaseUnited Kingdom
Clinical Trials on exercise group
-
University of ReginaUniversity of Saskatchewan; Saskatchewan Health Research Foundation; First Steps...RecruitingMultiple Sclerosis | Multiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary ProgressiveCanada
-
University of Colorado, DenverTemple University; Virginia Commonwealth University; University of Colorado,... and other collaboratorsCompleted
-
Shanghai Pudong HospitalUnknown
-
University of OxfordOxford Brookes UniversityRecruitingOverweight/Obesity, AdolescentUnited Kingdom
-
Istanbul University - CerrahpasaRecruitingLateral EpicondylitisTurkey
-
Hasselt UniversityRecruitingGestational Hypertension | Cardiovascular Pregnancy ComplicationBelgium
-
Tel Aviv UniversityHadassah Medical OrganizationWithdrawnBreast Cancer | Colon CancerIsrael
-
Marmara UniversityRecruiting
-
International Hellenic UniversityCompleted
-
Muğla Sıtkı Koçman UniversityRecruitingChronic Neck PainTurkey